ImmunityBio reports Phase 3 ANKTIVA-plus-BCG bladder cancer data
ImmunityBio reports 84% cystectomy avoidance at three years and complete responses beyond 53 months in patients with BCG-unresponsive NMIBC, with or without papillary tumors.
ImmunityBio reports 84% cystectomy avoidance at three years and complete responses beyond 53 months in patients with BCG-unresponsive NMIBC, with or without papillary tumors.